Spanish Distributor Places Order for 400,000 MiraCare(TM) Tests HALIFAX, Jan. 11 /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF) the global market leader in premium rapid diagnostic solutions, announced today that it has received an order for 400,000 MiraCare(TM) Rapid HIV Antibody Tests (MiraCare(TM)) from its distributor in Spain. This is the first significant order of the MiraCare(TM) tests destined for the European market. MiraCare(TM), launched in 2005 in Hong Kong and Macao, will be sold in the 25 member countries of the European Union (EU). MedMira will fulfill this order over a preset timeframe, upon receipt of CE Mark. MiraCare(TM) will be the fastest rapid HIV test available in Europe, taking less than three minutes to perform and providing test results instantly. It will also be the first and only North American made rapid HIV test to be approved and sold in Europe. "This order is a significant milestone for MedMira in Europe. It is just the beginning of our strategic market push throughout the region," said Stephen Sham, chairman and CEO of MedMira. "We have put a great deal of time and effort into establishing a solid network of qualified distributors and obtaining regulatory approval necessary to bring MiraCare(TM) to the EU market." Sham continued, "We believe that our product will offer individuals and healthcare providers across Europe a far superior choice in rapid HIV testing." The distributor will target both near-patient settings such as pharmacies and hospitals, as well as laboratories for initial sales of the MiraCare(TM) test. MiraCare(TM) will be approved for whole blood, as well as serum and plasma specimens, making it a truly versatile rapid HIV test for all types of settings. It is sold as a complete test kit with all components required to perform the test. MiraCare(TM) will be an important diagnostic tool in combating Europe's growing HIV epidemic. EuroHIV, the European HIV/AIDS surveillance network, estimates that over 2 million people in Europe are living with HIV, and infection rates are on the rise. According to UNAIDS, 100,000 new cases of HIV were diagnosed in 2004 in Europe. About MedMira MedMira is the leading global manufacturer and marketer of in vitro flow- through rapid diagnostic tests. MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV and hepatitis C. The United States FDA and the SFDA in the People's Republic of China have approved MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests, respectively. MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests are currently used in clinical laboratories, hospitals, and clinics where professional counselling and patient treatment are immediately available. The MiraCare(TM) Rapid HIV Antibody Test, MedMira's over-the-counter (OTC) product, is available in pharmacies throughout Hong Kong and Macao Special Administrative Regions, in the People's Republic of China. MedMira delivers rapid diagnostic solutions to healthcare communities around the globe. Its corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in Guilin, China. This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. For more information visit MedMira's website at http://www.medmira.com/. DATASOURCE: MedMira Inc. CONTACT: Dr. James Smith, Investor Relations, Tel: (902) 450-1588, E-mail: ; Andrea Young, Corporate Communications, Tel. (902) 450-1588, Email:

Copyright